Bellevue Group AG Sells 2,079 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bellevue Group AG decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 91,279 shares of the company's stock after selling 2,079 shares during the quarter. Bellevue Group AG owned 0.11% of IDEXX Laboratories worth $46,116,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Chicago Partners Investment Group LLC raised its stake in shares of IDEXX Laboratories by 16.7% in the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after acquiring an additional 96 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in IDEXX Laboratories during the 2nd quarter worth about $20,418,000. Oppenheimer Asset Management Inc. grew its position in shares of IDEXX Laboratories by 13.8% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock valued at $5,825,000 after acquiring an additional 1,453 shares during the period. National Pension Service increased its stake in shares of IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after purchasing an additional 12,647 shares during the last quarter. Finally, EFG Asset Management Americas Corp. increased its position in IDEXX Laboratories by 45.3% during the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock worth $6,201,000 after buying an additional 3,966 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company's stock, valued at $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.11% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IDXX. Piper Sandler reiterated a "neutral" rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. Barclays decreased their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. Finally, StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $552.38.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded down $0.01 during trading on Friday, reaching $421.75. The company had a trading volume of 338,607 shares, compared to its average volume of 672,036. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average of $451.91 and a two-hundred day moving average of $477.81. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The stock has a market capitalization of $34.54 billion, a P/E ratio of 40.67, a price-to-earnings-growth ratio of 3.68 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to analysts' expectations of $980.32 million. During the same period last year, the firm posted $2.53 EPS. IDEXX Laboratories's revenue for the quarter was up 6.6% compared to the same quarter last year. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.